By Folasade AkpanAnnually, on Feb. 15, the International Childhood Cancer Day (ICCD) is commemorated as a global campaign to create awareness about childhood cancer and support for the patients, ...

Results from a new study published in Clinical and Translational Immunology found that dual-target antibody therapy can enhance cancer-fighting T cells more effectively than current single-target ...

Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

Alphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.

Scientists have unlocked the mysteries of the 'extracellular matrix' which holds tumours together and the discovery could ...

Having raised more than $1 million toward cancer research over the past nine years, the tournament is on the road to raising ...

Cancer cells have special adaptation mechanisms that allow them to proliferate despite changes in their genetic makeup.

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Two new studies represent a big step toward developing innovative molecular therapies capable of disrupting the ...